Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Feb 17, 2016
Trial Information
Current as of September 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special laboratory technique called targeted genomic analysis, which studies the genetic information in blood and tissue samples from patients with cancer. By examining the genetic makeup of cancer cells, researchers hope to identify changes that may contribute to the growth of certain types of cancer. This information could help doctors find better ways to diagnose and treat patients, especially those with rare cancers that are difficult to treat and have a poor outlook.
To participate in this study, individuals should have a confirmed diagnosis of cancer, particularly those with rare types or those who have not responded well to standard treatments. Participants need to be able to carry out daily activities (a performance score of 30 or higher) and must provide written consent. The study will prioritize patients who have tumor samples available for analysis. Those who are facing a life expectancy of less than three months or have a performance score below 30 will not be eligible. If you join this trial, you can expect to contribute to important research that could improve cancer treatment for many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Karnofsky/Lansky performance score \>= 30
- • A signed written informed consent
- • Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
- • Paraffin blocks of the patient's tumor tissue are available and accessible for analysis
- Exclusion Criteria:
- • Karnofsky/Lansky performance score \< 30
- • Life expectancy \< 3 months
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Red Bank, New Jersey, United States
Summit, New Jersey, United States
New Brunswick, New Jersey, United States
Madison, Wisconsin, United States
Neptune, New Jersey, United States
Morristown, New Jersey, United States
Red Bank, New Jersey, United States
Brick, New Jersey, United States
Manahawkin, New Jersey, United States
Holmdel, New Jersey, United States
Jersey City, New Jersey, United States
Patients applied
Trial Officials
Shridar Ganesan
Principal Investigator
Rutgers Cancer Institute of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials